Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 11:10 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 97–120 of 640 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Transfusion Clear all
Completed No phase listed Observational

Transfusion Requirements During Spinal Surgery for Severe Scoliosis

NCT01490164
View directory record Official record
Conditions
Scoliosis
Interventions
Not listed
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
Up to 19 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Newark, New Jersey
Source: ClinicalTrials.gov public record
Updated Nov 13, 2013 · Synced Oct 21, 2026, 11:10 PM EDT
Completed Phase 1Phase 2 Interventional Results available

A Study to Assess the Safety, Tolerability, and Efficacy of ST-400 for Treatment of Transfusion-Dependent Beta-thalassemia (TDT)

NCT03432364
View directory record Official record
Conditions
Transfusion Dependent Beta-thalassemia
Interventions
ST-400 Investigational product
Genetic
Lead sponsor
Sangamo Therapeutics
Industry
Eligibility
18 Years to 40 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
6
States / cities
Los Angeles, California • Oakland, California • Atlanta, Georgia + 3 more
Source: ClinicalTrials.gov public record
Updated Dec 14, 2023 · Synced Oct 21, 2026, 11:10 PM EDT
Completed Phase 3 Interventional Results available

Low-Titer O Positive Whole Blood Versus Component Therapy for Emergent Transfusion in Trauma Patients

NCT05081063
View directory record Official record
Conditions
Hemorrhagic Shock, Acute Blood Loss Anemia, Traumatic Brain Injury
Interventions
Routine labs
Combination Product
Lead sponsor
Loma Linda University
Other
Eligibility
18 Years and older · Male only
Enrollment
199 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Loma Linda, California
Source: ClinicalTrials.gov public record
Updated Aug 8, 2025 · Synced Oct 21, 2026, 11:10 PM EDT
Not listed No phase listed Observational

Blood Transfusion by Boston MedFlight Registry

NCT04610814
View directory record Official record
Conditions
Hemorrhagic Shock
Interventions
Not listed
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 1, 2021 · Synced Oct 21, 2026, 11:10 PM EDT
Terminated Not applicable Interventional Results available

Treatment of Sickle Cell Anemia With Stem Cell Transplant

NCT01350232
View directory record Official record
Conditions
Sickle Cell Anemia, Sickle Cell-hemoglobin C Disease, Sickle Cell-β0-thalassemia
Interventions
Fludarabine, Cytarabine, Cellular Infusions, Total Body Irradiation, Cyclophosphamide, Bortezomib, Rituximab, Plasmapheresis
Drug · Device · Radiation + 1 more
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Other
Eligibility
18 Years to 45 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 16, 2025 · Synced Oct 21, 2026, 11:10 PM EDT
Completed Phase 1 Interventional

Young Plasma Transfusions for Progressive Supranuclear Palsy

NCT02460731
View directory record Official record
Conditions
Progressive Supranuclear Palsy
Interventions
Fresh Frozen Plasma
Biological
Lead sponsor
University of California, San Francisco
Other
Eligibility
50 Years to 85 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Aug 11, 2020 · Synced Oct 21, 2026, 11:10 PM EDT
Not listed No phase listed Observational

Management and Outcomes of Anti-thrombotic Medication Use in Thrombocytopenia

NCT03288441
View directory record Official record
Conditions
Hematologic Neoplasms, Thrombocytopenia, Anticoagulants, Platelet Aggregation Inhibitors
Interventions
Hold, Prophylactic dose antithrombotic, Change antithrombotic Drug, Change platelet transfusion threshold, Full dose antithrombotics, Mechanical measures, Intermediate dose antithrombotic
Drug · Biological · Device
Lead sponsor
Maastricht University Medical Center
Other
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Sep 17, 2020 · Synced Oct 21, 2026, 11:10 PM EDT
Completed No phase listed Observational

Management of Bleeding Following Cardiopulmonary Bypass

NCT00672516
View directory record Official record
Conditions
Hemorrhage, Cardiopulmonary Bypass
Interventions
Not listed
Lead sponsor
University of Minnesota
Other
Eligibility
Up to 75 Years
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated May 28, 2015 · Synced Oct 21, 2026, 11:10 PM EDT
Completed Phase 2 Interventional Results available

Optimized Erythropoietin (EPO) Treatment

NCT02075970
View directory record Official record
Conditions
Neonatal Anemia
Interventions
Epoetin Alpha
Drug
Lead sponsor
University of Iowa
Other
Eligibility
Up to 2 Days
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Jul 23, 2026 · Synced Oct 21, 2026, 11:10 PM EDT
Completed Phase 2 Interventional Results available

Selinexor (KPT-330) in Older Patients With Relapsed AML

NCT02088541
View directory record Official record
Conditions
Acute Myeloid Leukemia (AML)
Interventions
Selinexor, Hydroxyurea, Ara-C
Drug
Lead sponsor
Karyopharm Therapeutics Inc
Industry
Eligibility
60 Years and older
Enrollment
317 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
26
States / cities
Los Angeles, California • Sacramento, California • Stanford, California + 20 more
Source: ClinicalTrials.gov public record
Updated Jan 26, 2023 · Synced Oct 21, 2026, 11:10 PM EDT
Completed Phase 3 Interventional

Eculizumab in Treating Patients With Paroxysmal Nocturnal Hemoglobinuria

NCT00112983
View directory record Official record
Conditions
Leukemia
Interventions
eculizumab
Biological
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 30, 2013 · Synced Oct 21, 2026, 11:10 PM EDT
Terminated Phase 2 Interventional Results available

Efficacy and Safety of Lenalidomide in Combination With Cyclosporine A in Patients With Myelodysplastic Syndromes

NCT00840827
View directory record Official record
Conditions
Myelodysplastic Syndrome
Interventions
lenalidomide, cyclosporine A
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 19, 2019 · Synced Oct 21, 2026, 11:10 PM EDT
Completed Not applicable Interventional

The DETECT HCV Screening Trial

NCT04003454
View directory record Official record
Conditions
Hepatitis C
Interventions
HCV Screening
Other
Lead sponsor
Denver Health and Hospital Authority
Other
Eligibility
18 Years and older
Enrollment
147,533 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
3
States / cities
Denver, Colorado • Baltimore, Maryland • Jackson, Mississippi
Source: ClinicalTrials.gov public record
Updated Feb 6, 2025 · Synced Oct 21, 2026, 11:10 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Placental Transfusion in Term Infants: A Pilot Study

NCT01924572
View directory record Official record
Conditions
Anemia
Interventions
cord clamping at 2 minutes, cord clamping at 5 minutes, cord milking
Procedure
Lead sponsor
University of Rhode Island
Other
Eligibility
18 Years to 45 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Aug 16, 2013 · Synced Oct 21, 2026, 11:10 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Cerebrovascular Reserve and White Matter Disease in Patients with Chronic Anemia

NCT03715972
View directory record Official record
Conditions
Thalassemia, Sickle Cell Disease, Healthy Controls
Interventions
Hydroxyurea, Acetazolamide
Drug
Lead sponsor
Children's Hospital Los Angeles
Other
Eligibility
7 Years and older
Enrollment
165 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2022
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Oct 30, 2024 · Synced Oct 21, 2026, 11:10 PM EDT
Completed Phase 4 Interventional Results available

Rejuvesol® Washed RBC in Sickle Cell Patients Requiring Frequent Transfusions

NCT02731157
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Rejuvesol, Blood transfusion
Drug · Procedure
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
2
States / cities
Chapel Hill, North Carolina • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 25, 2019 · Synced Oct 21, 2026, 11:10 PM EDT
Terminated Phase 1 Interventional

Antithrombin III Supplementation for Cardiopulmonary Bypass in Neonates

NCT01158729
View directory record Official record
Conditions
Postoperative Hemorrhage
Interventions
Antithrombin (Recombinant), Placebo
Drug · Other
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
4 Days to 30 Days
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jan 20, 2014 · Synced Oct 21, 2026, 11:10 PM EDT
Completed Phase 4 Interventional

Efficacy of Pathogen Inactivation Strategies for Platelet Transfusion

NCT06535360
View directory record Official record
Conditions
Cardiopulmonary Bypass Surgery
Interventions
Platelet transfusion
Biological
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 6, 2024 · Synced Oct 21, 2026, 11:10 PM EDT
Suspended Phase 2Phase 3 Interventional

Phase II Study To Evaluate The Safety and Efficacy of Hemoglobin Raffimer in Patients Undergoing First Time CABG Surgery

NCT00038454
View directory record Official record
Conditions
Cardiovascular Disease
Interventions
Hemolink (hemoglobin raffimer IV solution)
Drug
Lead sponsor
Hemosol
Industry
Eligibility
18 Years to 80 Years
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
19
States / cities
San Francisco, California • Stanford, California • Sarasota, Florida + 14 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 21, 2026, 11:10 PM EDT
Completed Phase 2 Interventional Results available

A Study to Determine the Efficacy and Safety of Luspatercept in Adults With Non Transfusion Dependent Beta (β)-Thalassemia

NCT03342404
View directory record Official record
Conditions
Thalassemia
Interventions
Luspatercept, Placebo, Best Supportive Care (BSC)
Drug · Other
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
145 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
4
States / cities
Los Angeles, California • Oakland, California • Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Dec 20, 2023 · Synced Oct 21, 2026, 11:10 PM EDT
Not listed Phase 1 Interventional Accepts healthy volunteers

Cold Apheresis Platelets in PAS

NCT02754414
View directory record Official record
Conditions
Platelet Transfusion
Interventions
Apheresis platelet collection, Refrigerated storage of apheresis platelets in PAS/plasma, Infusion of aliquot of autologous radiolabeled platelets, In vitro tests
Procedure · Other · Radiation
Lead sponsor
Bloodworks
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2019
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated May 14, 2018 · Synced Oct 21, 2026, 11:10 PM EDT
Terminated Not applicable Interventional Results available

Efficacy and Safety of RBCs Derived From Mirasol-treated Whole Blood in Patients Requiring Chronic Transfusion (PRAISE)

NCT03329404
View directory record Official record
Conditions
Transfusion Dependent Thalassemia
Interventions
Mirasol Red Blood Cells (MIR RBCs), Reference Red Blood Cells (REF RBCs)
Device
Lead sponsor
Terumo BCTbio
Industry
Eligibility
12 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
4
States / cities
Oakland, California • Boston, Massachusetts • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 14, 2024 · Synced Oct 21, 2026, 11:10 PM EDT
Recruiting Phase 1Phase 2 Interventional

RH Genotype Matched RBC Transfusions

NCT04156893
View directory record Official record
Conditions
Sickle Cells Disease
Interventions
Red cell units that are genotype matched at the RHD and RHCE loci
Biological
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
6 Months and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2029
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 27, 2026 · Synced Oct 21, 2026, 11:10 PM EDT
Recruiting Phase 4 Interventional Accepts healthy volunteers

Improving White Blood Cell Collection From Healthy Donors

NCT01553214
View directory record Official record
Conditions
Allogeneic Granulocyte Donation
Interventions
Filgrastim, Dexamethasone
Drug
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
18 Years to 75 Years
Enrollment
1,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2032
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 2, 2026 · Synced Oct 21, 2026, 11:10 PM EDT